Incidence and seasonality of respiratory viruses among medically attended children with acute respiratory infections in an Ecuador birth cohort, 2011–2014

Eduardo Azziz-Baumgartner1 | Alfredo Bruno2,3 | Michael Daugherty1 | Martha E. Chico4 | Andrea Lopez5 | Carmen Sofia Arriola1 | Domenica de Mora1 | Alba María Ropero6 | William W. Davis1 | Meredith McMorrow7 | Philip J. Cooper5,8

1International Epidemiology and Research Team, Influenza Division, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA
2Faculty of Veterinary Medicine and Zootechnics, Universidad Agraria del Ecuador, Guayaquil, Ecuador
3National Reference Laboratory for Influenza and Other Respiratory Viruses, Instituto Nacional de Investigación en Salud Pública (INSPI), Guayaquil, Ecuador
4Fundación Ecuatoriana Para Investigación en Salud, Quinindé, Ecuador
5School of Medicine, Universidad Internacional del Ecuador, Quito, Ecuador
6Immunizations Program, Pan American Health Organization, Washington, DC, USA
7Enhanced Surveillance Platforms Team, Division of Viral Diseases, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA
8Institute of Infection and Immunity, St George’s University of London, London, UK

Correspondence
Eduardo Azziz-Baumgartner, International Epidemiology and Research Team, Influenza Division, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30333, USA.
Email: eha9@cdc.gov

Funding information
Wellcome Trust, Grant/Award Number: 088862/Z/09/Z

Abstract
Background: Ecuador annually has handwashing and respiratory hygiene campaigns and seasonal influenza vaccination to prevent respiratory virus illnesses but has yet to quantify disease burden and determine epidemic timing.

Methods: To identify respiratory virus burden and assess months with epidemic activity, we followed a birth cohort in northwest Ecuador during 2011–2014. Mothers brought children to the study clinic for routine checkups at ages 1, 2, 3, 5, and 8 years or if children experienced any acute respiratory illness symptoms (e.g., cough, fever, or difficulty breathing); clinical care was provided free of charge. Those with medically attended acute respiratory infections (MAARIs) were tested for common respiratory viruses via real-time reverse-transcription polymerase chain reaction (rRT-PCR).

Results: In 2011, 2376 children aged 1–4 years (median 35 months) were enrolled in the respiratory cohort and monitored for 7017.5 child-years (cy). The incidence of respiratory syncytial virus (RSV) was 23.9 (95% CI 17.3–30.5), influenza 10.6 (2.4–18.8), adenoviruses 6.7 (4.6–28.0), parainfluenzas 5.0 (2.3–10.5), and rhinoviruses, bocaviruses, human metapneumoviruses, seasonal coronaviruses, and enteroviruses <3/100 cy among children aged 12–23 months and declined with age. Most (75%) influenza detections occurred April–September.

Conclusion: Cohort children frequently had MAARIs, and while the incidence decreased rapidly among older children, more than one in five children aged 12–23 months tested positive for RSV, and one in 10 tested positive for influenza. Our findings suggest this substantial burden of influenza occurred more commonly during the winter Southern Hemisphere influenza season.

KEYWORDS
burden, children, Ecuador, influenza, respiratory syncytial virus


1 | BACKGROUND

There is insufficient information about the burden and timing of respiratory virus epidemics among young children in tropical low- and middle-income countries (LMICs) to adequately guide mitigation. Acute respiratory illnesses, typically caused by respiratory viruses, are common causes of morbidity among young children and are frequently associated with pneumonia, hospitalization, and death. Investment in their prevention and control depends, in part, on understanding their incidence and seasonality. Much is known about respiratory viruses in temperate high-income countries; comparatively little is known from tropical LMICs where most of the mortality occurs.

For example, in 2018, influenza caused >10 million acute respiratory infections among children aged <5 years. Such annual epidemics disproportionately affect tropical LMICs. Epidemics in more northern latitudes typically occur October–March; those in southern latitudes occur April–September, but it is often unclear when epidemics occur in tropical latitudes. Understanding when epidemics occur helps inform disease burden modeling, vaccine formulation selection, and vaccination timing. In the tropics, however, influenza epidemics can seem unpredictable and their associated disease burden poorly characterized.

Like influenza, respiratory syncytial virus (RSV) causes substantial morbidity and mortality. For example, in 2015, RSV caused >30 million acute respiratory infections and an estimated 59600 in-hospital deaths in children aged <5 years. While there are currently no RSV vaccines in use to mitigate this burden, there are several in development. Countries can use monoclonal antibodies during RSV epidemics to prevent RSV in high-risk children, but these are typically costly and infrequently used in LMICs. Like influenza, RSV epidemics in temperate countries typically occur during cool weather; RSV seasonality in humid, tropical climates, however, is not well characterized.

Ecuador, with three geoclimatic zones (coastal, Andean, and Amazonian), has complex respiratory virus epidemics and limited burden information to justify sustained investments in mitigation. In 2006, Ecuador’s Ministry of Public Health introduced influenza vaccination among pregnant women and infants aged 6 months through 5 years and subsequently recommended the use of antivirals for the treatment of persons with severe or progressive community acquired pneumonia during influenza epidemics. Ecuador is the only South American country, however, to use a Northern rather than Southern Hemisphere vaccine formulation against influenza illness in part because of uncertainty about its influenza seasonality. While Ecuador does not currently use monoclonal antibodies within the public health system to prevent severe RSV illness, it does launch annual handwashing and respiratory hygiene campaigns to prevent contagion with respiratory viruses.

To substantiate the need for investments in respiratory virus prevention and optimize the timing of interventions, we used systematically collected birth cohort data from Ecuador to (i) estimate the incidence of medically attended influenza, RSV, and other respiratory viruses; (ii) assess whether influenza incidence was highest during the April–September Southern Hemisphere season versus the October–March Northern Hemisphere season; and (iii) explore peak epidemic weeks of influenza and RSV activity.

2 | METHODS

A description of the Ecuador Life (ECUAVIDA) study has been previously published. In brief, a prospective birth cohort was established in Quinindé, Ecuador. From 2005 to 2009, staff enrolled newborns delivered at Hospital Padre Alberto Buffoni (HPAB). Inclusion criteria were (1) healthy newborns aged <14 days; (2) stool samples collected from mothers during pregnancy for helminth infections; (3) maternal age ≥17 years; (4) anticipated residence in Quinindé for ≥2 years; and (5) accessibility of households to the study teams. Of 4087 mothers–infant pairs evaluated for eligibility, 1683 (41%) did not fulfill all eligibility criteria (e.g., 525 [31.2%] were excluded because households could not routinely access the study clinic).

On January 1, 2011, children still participating in ECUAVIDA were consented into the respiratory cohort and followed prospectively to identify medically attended acute respiratory infections (MAARIs) until their eighth birthday or the end of sampling on June 30, 2014. During the study, mothers brought children to the HPAB clinic for routine checkups at ages 1, 2, 3, 5, and 8 years or if children experienced any acute respiratory illness symptoms (e.g., cough, fever, or difficulty breathing); clinical care was provided free of charge.

Study clinicians defined MAARI as nasopharyngitis, acute otitis media, sinusitis, laryngitis, epiglottitis, tracheitis, bronchitis, bronchiolitis, or pneumonia diagnosed at HPAB. Staff collected nasopharyngeal specimens using Dacron swabs from children with MAARI at the clinic. Specimens were stored at −80°C and shipped on dry ice to Ecuador’s National Reference Laboratory (NRL) for real-time reverse-transcription polymerase chain reaction (rRT-PCR) detection of influenza and immunofluorescence detection of other respiratory viruses using World Health Organization (WHO) protocols.

We calculated the incidence of MAARI and MAARI-associated respiratory viruses using previously described methods. We accounted for under-ascertainment of influenza, RSV, adenovirus, and parainfluenza virus 1–3 among children with MAARIs who were not swabbed by multiplying their frequency by the proportion of samples testing positive for these viruses at the NRL surveillance in the same age group and epidemic week. We calculated participating children’s person time as the number of days from study enrollment (January 1, 2011) to study conclusion (June 30, 2014), last completed checkup visit, or eighth birthday and excluded days when parents missed routine checkups and/or 14 days after a MAARI event. We also restricted the risk period to weeks when specific viruses were circulating in Ecuador according to NRL. Resulting rates incorporated the variance in the age-adjusted proportion of samples testing positive per epidemic week and the sensitivity of the immunofluorescence assay used by NRL to test surveillance samples for non-influenza viruses.

To assess influenza and RSV epidemic timing, we calculated the average proportion of samples testing positive for these viruses
each month; we did not assess the epidemic timing of other respiratory viruses because we did not anticipate sufficient detections for a meaningful analysis. The start of the epidemic was defined as the first month when the proportion of positive samples was greater than the annual mean for ≥2 months, and the end was defined as the first month when the proportion of influenza positive samples remained below the annual mean for ≥2 months.13 We also calculated the influenza rate ratio during April–September Southern Hemisphere season versus October–March Northern Hemisphere season.

The study protocol was approved by the Bioethics Committee of the Universidad San Francisco de Quito, Ecuador (Protocol 6-11-2010). Informed written consent for participation in the study was obtained from parents or legal guardians of children.

### RESULTS

In 2011, 2376 children aged 1–4 years (median 35 months) were enrolled in the respiratory cohort and accrued 7017.5 child-years (cy). Half (49%) of the children were female, and most (74%) were from mothers who self-identified as Mestizo (i.e., of mixed Spanish and indigenous descent, Table 1). Twenty-four percent had received at least one influenza vaccine between ages 6 and 24 months, and 17% had received two doses. The 1984 (84%) children who completed the study had similar demographics to those who did not; 221 (9%) moved from the study area, and 102 (4%) withdrew; 67 (3%) missed their last checkup, and two (0.1%) died because of unknown reasons.

Forty-one percent (964) of children were brought to the clinic with at least one MAARI (total of 2192 MAARIs) of which 718 (74%)...
were successfully swabbed; 437 (45%) had one; 232 (24%) two; 121 (13%) three; 74 (8%) four; and 100 (10%) ≥5 MAARIs. Children with MAARIs were more likely to be Afro-Ecuadorian than those without MAARIs (relative risk 1.2, 95% CI 1.1–1.3). The most common parental symptoms were cough (92%), congestion (70%), rhinorrhea (65%), fever (64%), poor appetite (50%), difficulty breathing (25%), wheezing (23%), irritability (17%), nausea (15%), and vomiting (13%). Upon examination, 20% of MAARIs were attributed to bronchitis, and 4% were prescribed antibiotics, commonly amoxicillin (56, 60%); none were prescribed antivirals.

Among the 964 children aged 12–95 months who were tested during a MAARI, 116 (12%) tested positive for rhinovirus, 97 (10%) influenza, 80 (8%) human bocavirus, 63 (7%) human metapneumovirus (HMPV), 61 (6%) parainfluenza 1–3, 60 (6%) RSV, 53 (5%) adenoviruses, 42 (4%) seasonal coronaviruses, and 11 (1%) enteroviruses. Upon examination, 20% of MAARIs were attributed to bronchitis, and 4% were prescribed antibiotics, commonly amoxicillin (56, 60%); none were prescribed antivirals.

Eighteen percent (n = 18) of the 97 influenza-positive and 27% (n = 16) of 60 RSV-positive MAARIs were associated with difficulty breathing. Overall MAARI incidence was 131.1/100 cy, peaking at 95.4/100 cy at age 12–23 months and declining to 69.6/100 cy at 24–35 months, and 23.1/100 cy at 36–95 months. The incidence of RSV was 23.9/100 cy (95% CI 17.3–30.5), influenza 10.6/100 cy (2.4–18.8), adenoviruses 6.7/100 cy (4.6–28.0), parainfluenzas 5.0/100 cy (2.3–10.5), and rhinoviruses, bocaviruses, HMPVs, seasonal coronaviruses, and enteroviruses <3/100 cy among children aged 12–23 months and declined with age (Figure 1) (Table 2).

4 | DISCUSSION

Cohort children frequently had MAARIs attributable to respiratory viruses. Indeed, almost all children aged 12–23 months had MAARIs,
| Age Group | Laboratory detections | Respiratory syncytial virus | Influenza | Adenovirus | Parainfluenza 1–3 | Rhinovirus |
|-----------|------------------------|-----------------------------|-----------|------------|-------------------|-----------|
| 12–95 months | Laboratory detections | 60 | 97 | 53 | 61 | 116 |
| Estimated among those missing swabs | 144 (134–155)* | 63 (54–71) | 10 (9–28) | 34 (25–44) | NA |
| Lab-confirmed and estimated illnesses | 204 (194–215) | 101 (93–110) | 63 (44–81) | 95 (86–105) | NA |
| Person time (years) | 7044 | 7044 | 7044 | 7044 | 7044 |
| Proportion of person time at risk | 0.80 | 0.77 | 0.43 | 0.81 | NA |
| Risk period (years) | 5612 | 5419 | 3019 | 5728 | NA |
| Rate/100 child-years | 3.6 (3.5–3.8) | 2.9 (2.8–3.1) | 2.1 (1.5–2.7) | 1.7 (1.5–1.8) | 1.65 |

| 12–23 months | Laboratory detections | 1 | 2 | 4 | 4 | 5 |
| Estimated among those missing swabs | 39 (27–48) | 9 (1–17) | 2 (1–20) | 5 (1–15) | NA |
| Lab-confirmed and estimated illnesses | 39 (28–49) | 11 (3–19) | 6 (1–24) | 9 (1–19) | NA |
| Person time (years) | 205 | 205 | 205 | 205 | 205 |
| Proportion of person time at risk | 0.79 | 0.50 | 0.42 | 0.87 | NA |
| Risk period (years) | 162 | 103 | 87 | 178 | NA |
| Rate/100 child-years | 23.9 (17.3–30.5) | 10.6 (4.9–18.8) | 6.7 (4.6–28.0) | 5.0 (2.3–10.5) | 2.4 |

| 24–35 months | Laboratory detections | 16 | 25 | 18 | 20 | 36 |
| Estimated among those missing swabs | 34 (23–45) | 11 (2–19) | 2 (1–21) | 6 (1–16) | NA |
| Lab-confirmed and estimated illnesses | 50 (39–61) | 36 (7–44) | 20 (1–39) | 26 (16–36) | NA |
| Person time (years) | 756 | 756 | 756 | 756 | 756 |
| Proportion of person time at risk | 0.72 | 0.61 | 0.37 | 0.87 | NA |
| Risk period (years) | 568 | 462 | 280 | 654 | NA |
| Rate/100 child-years | 8.8 (6.9–19.7) | 7.7 (5.9–9.6) | 7.2 (4.0–14.0) | 4.0 (3.1–5.5) | 4.8 |

| 36–95 months | Laboratory detections | 43 | 68 | 29 | 36 | 72 |
| Estimated among those missing swabs | 41 (18–65) | 48 (29–67) | 5 (36–47) | 18 (5–41) | NA |
| Lab-confirmed and estimated illnesses | 84 (61–108) | 116 (97–135) | 341 (7–76) | 54 (31–77) | NA |
| Person time (years) | 6104 | 6104 | 6104 | 6104 | 6104 |
| Proportion of person time at risk | 0.79 | 0.80 | 0.42 | 0.82 | NA |
| Risk period (years) | 4836 | 4886 | 2569 | 4983 | NA |
| Rate/100 child-years | 1.79 (1.3–2.2) | 2.4 (2.0–2.8) | 1.3 (0.3–3.0) | 1.1 (0.6–1.5) | 1.2 |

*Values represent 95% confidence interval of the variance in the age-adjusted proportion of surveillance samples positive for each respiratory virus on any given week and the sensitivity of the assay.
|          | Bocavirus | Human metapneumovirus | Coronaviruses 1, 48, 64, 226 | Enterovirus |
|----------|-----------|------------------------|-----------------------------|-------------|
| 12–95 months | 80        | 15                     | 42                          | 11          |
| NA       | NA        | NA                     | NA                          | NA          |
| 7044     | NA        | 7044                   | 7044                        | 7044        |
| NA       | NA        | NA                     | NA                          | NA          |
| 1.14     | 0.21      | 0.60                   | 0.60                        | 0.16        |
| 12–23 months | 6         | 4                      | 1                           | 2           |
| NA       | NA        | NA                     | NA                          | NA          |
| 205      | 205       | 205                    | 205                         | 205         |
| NA       | NA        | NA                     | NA                          | NA          |
| 2.9      | 1.9       | 0.5                    | 1.0                         | 1.0         |
| 24–35 months | 17        | 14                     | 11                          | 3           |
| NA       | NA        | NA                     | NA                          | NA          |
| 756      | 756       | 756                    | 756                         | 756         |
| NA       | NA        | NA                     | NA                          | NA          |
| 2.2      | 1.9       | 1.5                    | 1.5                         | 0.4         |
| 36–95 months | 57        | 45                     | 28                          | 6           |
| NA       | NA        | NA                     | NA                          | NA          |
| 6104     | 6104      | 6104                   | 6104                        | 6104        |
| NA       | NA        | NA                     | NA                          | NA          |
| 0.9      | 0.7       | 0.5                    | 0.5                         | 0.1         |

*Values represent 95% confidence interval of the variance in the age-adjusted proportion of surveillance samples positive for each respiratory virus on any given week and the sensitivity of the assay.*
and more than one in five tested positive for RSV and one in 10 for influenza. The incidence of respiratory viruses among this young age group is important because younger children are also at highest risk of viral\textsuperscript{14} and bacterial pneumonias\textsuperscript{15} and subsequent hospitalizations.\textsuperscript{16} Such a burden suggests the value of continued investment in Ecuador’s pharmaceutical and nonpharmaceutical interventions to

**FIGURE 2** Children with laboratory-confirmed influenza and respiratory syncytial virus (RSV) medically attended acute respiratory infection (MAARI) in the Esmeraldas Province birth cohort and percent of samples testing positive for each virus at the National Reference Laboratory (NRL) throughout Ecuador, 2011–2014

**FIGURE 3** Children with laboratory-confirmed influenza and respiratory syncytial virus (RSV) medically attended acute respiratory infection (MAARI) in the Esmeraldas Province birth cohort and weighted average percent of samples testing positive for each virus at the National Reference Laboratory (NRL) throughout Ecuador by epidemic week, 2011–2014
Rates of RSV among cohort children were on the higher range of those estimated for high-income countries and similar to those estimated from the few other tropical LMICs that have estimated such rates through cohort studies (e.g., Kenya). While there are currently no licensed vaccines to prevent RSV among infants, several are in development and might eventually be of value in mitigating the global burden of RSV. Monoclonal antibodies are currently available for the prevention of RSV illness among premature infants, but each dose is costly, and monoclonal antibodies are not currently included in Ecuador’s list of subsidized essential drugs. Additional studies might be beneficial to explore the cost–benefit of such monoclonal antibodies for high-risk infants in LMICs. Should providers in Ecuador choose to use monoclonal antibodies, these might be most cost-effective if used during the peak of the January–April RSV season.

The incidence of influenza among cohort children was similar to that of other upper-middle-income countries that invest in vaccination of young children. Despite a substantial burden, annual Ministry of Public Health vaccination campaigns, and free-of-charge vaccination initiated in 2006, only one in six cohort children was fully vaccinated against influenza during 2011–2014. Similarly, in a 2015–2016 study in Quito, only 36.6% of pregnant women targeted for vaccination had been vaccinated against influenza; the most common reason cited for not being vaccination was lack of a recommendation from a health care provider. It is unclear, however, if current vaccine coverage remains low in Ecuador. A recent PAHO report suggests that national vaccination coverage among Ecuador children, estimated through administrative methods, might have been >60% in 2014. Ecuador might therefore benefit from reevaluation of its vaccine program using standardized WHO tools to estimate current coverage, identify barriers to full influenza vaccination necessary for effective protection against hospitalization, and determine which steps are necessary to meet the WHO Immunization Agenda 2030 strategic goals.

In our study, 3/4 of laboratory-confirmed influenza occurred during April–September, the typical Southern Hemisphere season. Though influenza illnesses among children in Quinindé clustered in a Southern Hemisphere pattern, one of the four study years (2011) also had an epidemic during December in a Northern Hemisphere pattern. The Quinindé findings are similar to those of a multiyear cohort in neighboring Tumbes, Peru, where influenza activity occurred during the Northern and Southern hemisphere seasons; Cuzco, Lima, and Puerto Maldonado further to the south more often had influenza activity during the April–September Southern hemisphere season. If replicable in other regions within Ecuador, such findings suggest the potential value of primarily using Southern Hemisphere vaccine formulations and schedules in Ecuador and aligns with the 2015 PAHO Technical Advisory Group recommendations to vaccinate against influenza using the latest available formulations prior to the peak of influenza illnesses. The findings also suggest the potential value of empiric treatment with antivirals during peak influenza activity that, on average, occurred in June.

Our study, done in 2011–2014, found that children in Quinindé sporadically had MAARI associated with seasonal coronaviruses 1, 48, 64, and 226. Seasonal coronaviruses, while detectable, seemed to infrequently trigger health-seeking at the study clinic especially when compared with RSV, influenza, and other commonly tested respiratory viruses. It is unclear if SARS-CoV-2, which has caused substantial illness in Ecuador and globally, might in the future be overshadowed by RSV. In the meantime, the Ecuador NRL continues to test for SARS-CoV-2, tracking the spread of COVID-19 through its population. There may be important lessons about the use of nonpharmaceutical interventions to prevent COVID-19 in LMICs that might have wider application for the prevention of future seasonal respiratory virus epidemics.

Our study had strengths and limitations. Unlike other seasonality studies that used administrative data and modeling to estimate influenza epidemic periods, we used robust birth cohort data to calculate incidence of influenza-associated MAARIs and assess influenza epidemic periods. Though these data were robust, our study only incorporated information from households accessible to the study clinic, during 3.5 years, and from one rural coastal district (<1% of Ecuador’s population); our findings might therefore not represent influenza and RSV activity in other geographic regions of the country. Last, we could not adjust the incidence of rhinovirus, bocavirus, HMPV, coronaviruses, and enterovirus, by the number of unsampled cohort children who might have tested positive for these viruses, because the NRL did not routinely test surveillance samples for these viruses.

5 | CONCLUSION

Children in Quinindé frequently had RSV, influenza, and other respiratory virus-associated MAARI. On average, RSV activity occurred during January–April cooler weather months and influenza during April–September, the typical months of the Southern Hemisphere influenza season. If replicable in other microclimates in Ecuador, such findings suggest the potential value of influenza vaccine formulations to prevent illness. Influenza vaccination coverage during the study period, however, seemed lower than in other Latin American countries and suggests the benefit of reassessing the vaccination program and coverage using WHO post-introduction evaluation tools. It will also be important to assess the impact of respiratory mitigation through nonpharmaceutical interventions during the COVID-19 pandemic, which might yield important lessons about how to better prevent seasonal respiratory virus infections in LMICs.

CDC DISCLAIMER

The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the U.S. Centers for Disease Control and Prevention. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the United States Government.
INSPI DISCLAIMER
The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute of Public Health Research (INSPI). The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Ecuadorian Government.

ACKNOWLEDGEMENTS
We would like to thank Maritza Olmedo, Daniel Ehman, and Joel Montgomery for assisting with laboratory resources and procedures. Francisco Palomeque and Kate Woodworth in the early assembly of the data, Rakhee Palekar for helping us interpret surveillance findings, and Mary Ann Kirkconnell Hall for the critical review of the manuscript. The ECUAVIDA study was funded by Wellcome Trust grant 088862/Z/09/Z. Laboratory reagents were provided in kind through CDC’s International Reagent Resource https://www.internationalreagentresource.org/.

AUTHOR CONTRIBUTIONS
Eduardo Azziz-Baumgartner: Conceptualization; formal analysis; methodology; resources; supervision. Alfredo Bruno: Data curation; formal analysis; resources; supervision. Michael Daughtery: Data curation; formal analysis. Martha E. Chico: Data curation; investigation; project administration; validation. Andrea Lopez: Investigation; validation. Carmen Sofía Arriola: Conceptualization; formal analysis; methodology; supervision; validation. Domenica de Mora: Investigation; validation. Alba María Ropero: Supervision; validation. William W. Davis: Formal analysis; methodology; supervision; validation; visualization. Meredith McMorrow: Conceptualization; supervision; validation.

PEER REVIEW
The peer review history for this article is available at https://publons.com/publon/10.1111/irv.12887.

DATA AVAILABILITY STATEMENT
Data available on request from the authors.

ORCID
Eduardo Azziz-Baumgartner https://orcid.org/0000-0002-0298-5814
William W. Davis https://orcid.org/0000-0001-7062-9531
Meredith McMorrow https://orcid.org/0000-0001-6363-4033
Philip J. Cooper https://orcid.org/0000-0002-6770-6871

REFERENCES
1. Wang X, Li Y, O’Brien KL, et al. Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: a systematic review and modelling study. Lancet Glob Health. 2020;8(4):e497-e510.
2. Hirve S, Newman LP, Paget J, et al. Influenza seasonality in the tropics and subtropics—when to vaccinate? PLoS one. 2016;11(4): e0153003-e.
3. Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet (London, England). 2017; 390(10098):946-958.
4. Ampofo WK, Azziz-Baumgartner E, Bashir U, et al. Strengthening the influenza vaccine virus selection and development process: report of the 3rd WHO informal consultation for improving influenza vaccine virus selection held at WHO headquarters, Geneva, Switzerland, 1-3 April 2014. Vaccine. 2015;33(36):4368-4382.
5. Cai N, de Mora D, Olmedo M, et al. The epidemiology and severity of respiratory viral infections in a tropical country: Ecuador, 2009-2016. J Infect Public Health. 2019;12(3):357-363.
6. Palekar RS, Rolfes MA, Arriola CS, et al. Burden of influenza-associated respiratory hospitalizations in the Americas, 2010-2015. PLoS One. 2019;14(9):e0221479.
7. Erazo CE, Erazo CV, Grijalva MJ, Moncayo AL. Knowledge, attitudes and practices on influenza vaccination during pregnancy in Quito. Ecuador BMC Public Health. 2021;21(1):72.
8. Ecuador MdSPd. Neumonía adquirida en la comunidad en pacientes de 3 meses a 15 años. Guía de Práctica Clínica. Available at: https://www.salud.gob.ec/wp-content/uploads/2019/02/GPC_neumoni%C3%A1%CC%81a-adquirida_2017.pdf. Accessed April 16.
9. Durand LO, Cheng PY, Palekar R, et al. Timing of influenza epidemics and vaccines in the American tropics, 2002-2008, 2011-2014. Influenza Other Respi Viruses. 2016;10(3):170-175.
10. Cooper PJ, Chico ME, Platts-Mills TA, Strachan DP, Barreto ML. Cohort profile: the Ecuador Life (ECUAVIDA) study in Esmeraldas Province. Ecuador Int J Epidemiol. 2015;44(5):1517-1527.
11. Azziz-Baumgartner E, Cabrera AM, Chang L, et al. Mortality, severe acute respiratory infection, and influenza-like illness associated with influenza A(H1N1)pdm09 in Argentina, 2009. PLoS One. 2012;7(10): e47540.
12. Corvalán LP, Arias BG, Morales SP, González MR, Inostroza SJ, L Fl. Inmunofluorescencia indirecta versus reacción de polimerasa en cadena para el diagnóstico de virus respiratorios en niños ingresados en un hospital de la Región Metropolitana. Rev Chilena Infectol. 2019; 36(1):26-31.
13. Azziz Baumgartner E, Dao CN, Nasreen S, et al. Seasonality, timing, and climate drivers of influenza activity worldwide. J Infect Dis. 2012; 206(6):838-846.
14. Homaira N, Luby SP, Petri WA, et al. Incidence of respiratory virus-associated pneumonia in urban poor young children of Dhaka, Bangladesh, 2009-2011. PLoS One. 2012;7(2):e32056.
15. Kubale J, Kuan G, Gresh L, et al. Individual-level association of influenza infection with subsequent pneumonia: a case-control and prospective cohort study. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2020.
16. Nasreen S, Luby SP, Brooks WA, Homaira N, Mamun AA, et al. Population-based incidence of severe acute respiratory virus infections among children aged <5 years in rural Bangladesh, June–October 2010. PLoS ONE. 2014;9(2):e89978.
17. Chicaiza-Ayala WH-TA, Ortiz-Prado E, Douce RW, Coral-Almeida M. The burden of acute respiratory infections in Ecuador 2011-2015. PLoS ONE. 2016;13(5):e0196650.
18. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. New England Journal of Medicine. 2009;360(6):588-598.
19. Emukule GOKS, McMorrow ML, Ochola R, Otieno N, Widdowson M-A, et al. The burden of influenza and RSV among inpatients and outpatients in rural Western Kenya. 2009–2012. PLoS ONE. 2014;9(8):e105543.
20. PATH. RSV Clinical Trial Tracker. Available at: https://www.path.org/resources/rsv-and-mab-trial-tracker/RSV Accessed April 16.
21. Langley GF, Anderson LJ. Epidemiology and prevention of respiratory syncytial virus infections among infants and young children. Pediatr Infect Dis J. 2011;30(6):510-517.
22. Tinoco YO, Azziz-Baumgartner E, Uyeki TM, et al. Burden of influenza in 4 ecologically distinct regions of Peru: household active surveillance of a community cohort, 2009-2015. Clin Infect Dis. 2017; 65(9):1532-1541.

23. Ropero-Álvarez AM, el Omeiri N, Kurtis HJ, Danovaro-Holliday MC, Ruiz-Matus C. Influenza vaccination in the Americas: progress and challenges after the 2009 A(H1N1) influenza pandemic. Hum Vaccin Immunother. 2016;12(8):2206-2214.

24. Sofia Arriola C, el Omeiri N, Azziz-Baumgartner E, et al. Influenza vaccine effectiveness against hospitalizations in children and older adults—data from South America, 2013-2017. A Test Negative Design Vaccine X. 2019;3:100047.

25. Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med. 2014;2(5): 395-404.

26. PAHO. SARINet FluNet Home Page. Available at: http://ais.paho.org/phip/viz/ed_flu.asp. Accessed April 16.

27. Olsen SJA-BE, Budd AP, et al. Decreased influenza activity during the COVID-19 pandemic—United States, Australia, Chile, and South Africa, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(37): 1305-1309.

28. WHO. Influenza Vaccine Post-Introduction Evaluation (IPIE). Available at: https://www.who.int/immunization/research/development/ipie_influenza_post_introduction_evaluation/en/. Accessed May 22.

How to cite this article: Azziz-Baumgartner E, Bruno A, Daugherty M, et al. Incidence and seasonality of respiratory viruses among medically attended children with acute respiratory infections in an Ecuador birth cohort, 2011-2014. Influenza Other Respi Viruses. 2022;16(1):24-33. doi: 10.1111/irv.12887